Abstract
Autologous stem cell transplantation (ASCT) plays a significant role in the treatment of multiple myeloma. Although the result of STaMINA trial showed no extra survival benefit of second transplantation or consolidation therapy in addition to single ASCT, there is still an argument about the optimal treatment intensity. In the light of the patient's QOL and the cost, the effect of the post ASCT treatment has not been well discussed. Therefore, we investigated the impact of the single and tandem ASCT on the QALY and the cost.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
